Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin2015651525559415
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-Analyses Collaborative GroupChemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsJ Clin Oncol200826284617462518678835
   PubMed Web of Science ®Google Scholar
• ArdizzoniABoniLTiseoMCisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysisJ Natl Cancer Inst2007991184785717551145
   PubMed Web of Science ®Google Scholar
• DelbaldoCMichielsSSyzNBenefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysisJAMA2004292447048415280345
   PubMed Web of Science ®Google Scholar
• HerbstRSHeymachJVLippmanSMLung cancerN Engl J Med20083591367138018815398
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small cell lung cancerN Engl J Med20103631693170320979469
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small cell lung cancerNature200744856156617625570
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med20133682385239423724913
   PubMed Web of Science ®Google Scholar
• ShawATKimDWMehraRCeritinib in ALK-rearranged non-small cell lung cancerN Engl J Med20143701189119724670165
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• IwaharaTFujimotoJWenDMolecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous systemOncogene19971444394499053841
   PubMed Web of Science ®Google Scholar
• ChoiYLTakeuchuKSodaMIdentification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancerCancer Res2010162255815590
   Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res20091593143314919383809
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchiKA mouse model for EML4-ALK positive lung cancerProc Natl Acad Sci U S A200810550198931989719064915
   PubMed Web of Science ®Google Scholar
• OkamotoINakagawaKEchinoderm microtubule-associated protein-like 4-anaplastinc lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspectsCancer Sci201210381391139622568572
   PubMed Web of Science ®Google Scholar
• SasakiTRodigSJChirieacLRJannePAThe biology and treatment of EML4-ALK non-small cell lung cancerEur J Cancer201046101773178020418096
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWFirst-line crizotinib versus che-motherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN)Clinical Practice Guidelines in Oncology. Version 5Fort Washington PANCCN2015
   Google Scholar
• MassarelliEPapadimitrakopoulouVCeritinib for the treatment of late-stage (metastatic) non-small cell lung cancerClin Cancer Res201521467067425564153
   PubMed Web of Science ®Google Scholar
• IaconoDChiariRMetroGFuture options for ALK-positive non-small cell lung cancerLung Cancer20158721121925601484
   PubMed Web of Science ®Google Scholar
• LoongHMokKLeungLMokTCrizotinib in the management of advanced non-small cell lung cancerFuture Oncol201511573574525757678
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120ra17
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res2012181472148222235099
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashitaTEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med20103631734173920979473
   PubMed Web of Science ®Google Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discov2014466267324675041
   PubMed Web of Science ®Google Scholar
• ShackelfordREVoraMMayhallKCotelingamJALK-rearrangements and testing methods in non-small cell lung cancer: a reviewGenes Cancer2014511424955213
   PubMedGoogle Scholar
• SangJAcquavivaJFriedlandJCTargeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerCancer Discov2013343044323533265
   PubMed Web of Science ®Google Scholar
• GalkinAMelnickJKimSIdentification of NVP-TAE684, a potent, selective, efficacious inhibitor of NPM-ALKProc Natl Acad Sci U S A2007104127027517185414
   PubMed Web of Science ®Google Scholar
• MarsiljeTHPeiWChenBSynthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (LAK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,3-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsJ Med Chem2013565675569023742252
   PubMed Web of Science ®Google Scholar
• NiZZhangTCComputationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancerJ Mol Model20152117526084268
   PubMed Web of Science ®Google Scholar
• KhozinSBlumenthalGZhangLFDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerClin Cancer Res201521112436243925754348
   PubMed Web of Science ®Google Scholar
• NishoMMurakamiHHoriikeAPhase I study of ceritinib (LDK378) in Japanese patients with advanced anaplastic lymphoma kinase rearranged non-small cell lung cancer or other tumorsJ Thorac Oncol2015101058106626020125
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsLDK378 versus chemotherapy in ALK rearranged (ALK positive) patients previously treated with chemotherapy (platinum doublet) and Crizotinib Available from: https://clinicaltrials.gov/ct2/show/NCT01828112. NLM Identifier: NCT01828112Accessed July 17, 2015
   Google Scholar
• Novartis PharmaceuticalLDK378 versus chemotherapy in previously untreated patients with ALK rearranged non-small cell lung cancer Available from: https://clinicaltrials.gov/ct2/show/NCT01828099. NLM Identifier: NCT01828099Accessed July 17, 2015
   Google Scholar
• Zycadia™ (Ceritinib) [product information]East Hanover, NJNovartis Pharmaceuticals2014 Available from: www.pharma.us-novartis.com
   Google Scholar
• CooperMChimHChanHDurandCCeritinib: a new tyrosine kinase inhibitor for non-small cell lung cancerAnn Pharmacother201549110711225258420
   PubMed Web of Science ®Google Scholar
• KatayamaRLovlyCShawATherapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicineClin Cancer Res201521102227223525979929
   PubMed Web of Science ®Google Scholar
• KatayamaRFribouletLKoikeSTwo novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibClin Cancer Res201420225686569625228534
   PubMed Web of Science ®Google Scholar
• SequistLVGettingerSSenzerNNActivity of IPI-504, a novel heat shock protein 90 inhibitor, in patients with molecularly defined non-small cell lung cancerJ Clinc Oncol20102849534960
   PubMed Web of Science ®Google Scholar
• SocinskiMAGoldmanJEl-HaririIA multicenter phase 2 study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerClin Caner Res20131930683077
   PubMed Web of Science ®Google Scholar
• CamidgeDRKonoSALuXAnaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexedJ Thorac Oncol20116477478021336183
   PubMed Web of Science ®Google Scholar
• CrystalASShawASequistLPatient-derived models of acquired resistance can identify effective drug combination for cancerScience20143461480148625394791
   PubMed Web of Science ®Google Scholar
• AkbayEAKoyamaSCarreteroJActivation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsCancer Discov201331355136324078774
   PubMed Web of Science ®Google Scholar
• AzumaKOtaKKawaharaAassociation of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancerAnn Oncol2014251935194025009014
   PubMed Web of Science ®Google Scholar
• VannemanMDranoffGCombining immunotherapy and targeted therapies in cancer treatmentNat Rev Cancer201212423725122437869
   PubMed Web of Science ®Google Scholar
• RocheHoffman-LaALEX study: a randomized, phase iii study comparing alectinib with crizotinib in treatment-naive anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (NSCLC) patients Available from: https://clinicaltrials.gov/ct2/show/NCT02075840. NLM Identifier: NCT02075840Accessed July 17, 2015
   Google Scholar